Exchange: NYSE·Updated 07:34 PM EDT
News
all
press releases
Will Pharma and Specialty Demand Boost Cardinal Health's Q4 Results?
Cardinal Health heads into Q4 earnings with pharma, specialty and higher-margin businesses in focus as investors watch if growth offsets pricing headwinds.
Zacks
More News
COR Stock Gains as Q3 Earnings Beat on Segment Growth, EPS View Raised
Cencora's fiscal Q3 EPS beats estimates as broad segment growth lifts profit, prompting a higher 2026 outlook despite a slight revenue miss.
Zacks
Cencora (COR) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Cencora (COR) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks
Cencora (COR) Surpasses Q3 Earnings Estimates
Cencora (COR) delivered earnings and revenue surprises of +2.52% and -0.16%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Cencora Q3 26 Earnings Conference Call 8:30 AM ET
(RTTNews) - Cencora Inc (COR) will host a conference call at 8:30 AM ET on August 5, 2026, to discuss Q3 26 earnings results...
Nasdaq News: Markets
Cencora Reports Fiscal 2026 Third Quarter Results
Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 third quarter ended June 30, 2026, revenue increased 5.1 percent year-over-year to $84.8 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.94 for the third quarter of...
Business Wire
What's in Store for These 4 Healthcare Companies This Earnings Season?
McKesson, Cencora, Solventum and PacBio head into earnings with resilient demand offset by tariffs, funding pressure and pricing challenges.
Zacks
DENTSPLY SIRONA to Post Q2 Earnings: What's in Store for the Stock?
XRAY's Q2 results are likely to reflect transformation investments, dealer inventory cuts and weak implants, while Wellspect growth offers support.
Zacks
Cencora to Report Q3 Earnings: Is a Beat Likely for the Stock?
COR's Q3 results could reflect specialty pharma strength, oncology expansion and margin gains, even as pricing dynamics and GLP-1 trends pressure revenues.
Zacks
Can AI-Driven Efficiency and Specialty Demand Boost MCK's Q1 Results?
McKesson heads into Q1 with AI-driven efficiency, specialty momentum and oncology growth in focus as pricing dynamics may temper revenues.
Zacks

Advertisement|Remove ads.